MHC-I antibodies in combination with anti-CD16 antibodies or IL-2 treatment, further inhibited cytotoxicity of human blood NK cells against several tumor cell lines when compared to an isotype antibody control (IgG1), unstimulated cells or cells stimulated only with IL-2 or CD16 (51). This evidence concerns the gene IL2 and neoplasm.